Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Strides Shasun Q4 net...

    Strides Shasun Q4 net loss at Rs 4.40 crore, shares tank 23 percent

    Written by Ruby Khatun Khatun Published On 2018-05-20T10:15:42+05:30  |  Updated On 20 May 2018 10:15 AM IST
    Strides Shasun Q4 net loss at Rs 4.40 crore, shares tank 23 percent

    New Delhi: Drug firm Strides Shasun reported a consolidated net loss of Rs 4.40 crore from the continuing operations.


    The company had posted a net profit of Rs 91.59 crore for the same period a year ago, Strides Shasun said in a BSE filing.


    Consolidated revenue from continuing operations of the company stood at Rs 664.15 crore. It was Rs 677.13 crore in the same period a year ago.


    For the fiscal year ended March this year, the company posted a consolidated net profit of Rs 70.22 crore. It was Rs 279.71 crore for the year-ago period.


    Consolidated revenue from continuing operations for the fiscal year ended March 2018 stood at Rs 2,839.38 crore. It was Rs 2,755.44 crore for the previous fiscal year.


    "The financial year 2017-18 was a difficult year for Strides. While we continue to build momentum with our strategy, our execution was far from satisfactory," Strides Shasun Group CEO and Managing Director Arun Kumar said.


    In 2018-19 company's clear focus will be on the improving the quality of growth which will deliver a strong bounce back in the second half of the financial year 2018-19, he added.

    Arun KumarFinancial resultsfourth quarternet lossnet profitQ4Strides Shasun
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok